Pharmaceutical Executive
Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.
Training to become a United States Navy SEAL (SEa, Land, and Air) is considered among the most intensive preparation in the world. The average successful Navy SEAL candidate spends over a year in a series of formal training environments, including a rigorous Boot Camp; Basic Underwater Demolition; Basic Parachute Training; and Advanced Specialty Training.
While most people focus on the physical challenges of SEAL training, few appreciate the arduous mental preparation that helps SEALs win a mission even before they conduct it. In his recent book, The Way of the Seal: Think Like an Elite Warrior to Lead and Succeed, former SEAL Mark Devine reveals many SEAL conceptual frameworks that can be used for not only military battles but also brand battles.
Photo: Thinkstock
Devine believes that "to win at anything, we must first control our minds." Pharmaceutical professionals, teams, and organizations can apply many of these conceptual practices to enhance their mental toughness and establish a winning attitude. Here are some of the most relevant SEAL principles to help pharmaceutical professionals succeed at an elite level.
Pharma professionals can leverage front-sight focus to complete prioritized projects, streamline their commitments, and start new initiatives without getting derailed. The FITS Process can help these professionals identify the three to five "highest value targets" or the essential action steps for winning against competitors.
Very few people have the ability, desire, or opportunity to become a Navy SEAL. However, pharma professionals can apply these cutting-edge approaches to learn the mental fortitude, leadership skills, and winning mentality of the world's most elite warriors.
Stan Bernard, MD, MBA, is President of Bernard Associates LLC. He can be reached at SBernardMD@BernardAssociatesLLC.com. Dr. Bernard is a member of Pharm Exec's Editorial Advisory Board.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.
2 Commerce Drive
Cranbury, NJ 08512